TGA’s new recall procedures went live on the 15th of January 2018. The update includes changes to definitions and descriptions –
removing some of the confusing terminology that previously existed. There’s new processes with greater flexibility and clarity – including some new flow charts. We take a look at how to plan for a recall – it happens to everyone sooner or later.
On December 28, CFDA released the draft regulations for inspection of overseas drug and medical device manufacturers. Domestically CFDA has been stepping up inspection efforts for several years, including unannounced and random audits. Now CFDA inspection is going global. We take a look at the proposed inspection program.
So you got your registration. It was hard, but you got there. All that pesky regulatory stuff is done and now you can get on with the real business of selling product. But, of course, it’s not the end of the story. Regulation is whole-of-product-life and postmarket monitoring matters. No more so than in China, where the latest changes in CFDA regulations mean renewals are now all about looking back at the postmarket record. If you haven’t paid attention to postmarket, expect to struggle with registration renewal. We take a look at the latest changes in China and how to be prepared.
Truth in Advertising of Devices and Drugs in Australia – TGA to in-source controls, remove pre-clearances
Australia’s Therapeutic Good Advertising Code is due for a revamp. Current reforms promise a more streamlined approach, more direct TGA control, and tougher penalties for those who get it wrong. But current reforms promise a more streamlined approach, more direct TGA control, and tougher penalties for those who get it wrong. We look at the announced and proposed changes and what this all means for consumers and the industry.
The Draft Amendment to Order 650 published by CFDA last month brings some good news around the streamlined reviews of medical device submissions in China and especially for manufacturers of Innovative Devices. Not only will manufacturers of innovative medical devices be exempted from providing proof of sales abroad to CFDA, the mandatory local type testing requirements are also abolished. Nevertheless, there still exist some challenges for the unwary.
Don't miss out, watch now...
Join us on March 19-20, 2018 in Yorba Linda, California for an exceptional event that will bring you face-to-face with local experts from India to Japan, China to Australia and more. Discover what it takes to succeed in APAC markets. Can’t make it to California in March? This is so good we are running it twice – also on February 1-2, 2018 in Zurich, Switzerland
Latest Events and Webinars
Serving the industry for close to 20 years, we bring a track record and credibility that is second to none. Choose a regulatory partner that combines deep expertise with a flexible, strategic approach and a commercial focus that never loses sight of your objective - market access.
Risk Assessments, Design Controls, Biocompatibility , Clinical Evaluation Reports we can provide comprehensive technical support to ensure compliant product development. We can prepare full regulatory submissions for Medical Devices (including medical software) IVDs and combination products. We have the depth of technical expertise and international experience you need to support your expanding business.
Product recall? Warning Letter? Audit failure? Cancellation of Registration? Don’t Panic! We are experienced in dealing directly with regulators to resolve postmarket issues smoothly and with minimum fuss.
A quality culture adds real value to your business and ensures compliance runs smoothly. Let us help you – with individual processes, independent internal audit support or building a complete system. We are experienced in ISO 13485 and 21CFR 820 (QSR) for design and manufacturer and in ISO 17025 and 21CFR 58 for laboratories.